Cabel,

You are asking pretty much the same question regarding 5-point MACE that you previously asked and that I answered.

As for expectations of repeating the %RRR for 5-point MACE as seen in the Phase 2 trials......there were less than 200 diabetic patients in the combined ASSURE/SUSTAIN analysis treated for ~ 6 months and this yielded a total of 14 5-point MACE events (of which only 3 were the hard 3-point MACE). I broke this down further in a previous post. I'm not including the more recent analysis with ASSERT because I don't have access to the publication. The number of diabetic patients and number of observed events in the combined ASSURE/SUSTAIN is not very large. BETonMACE will dwarf this number (2425 patients, even higher risk due to stricter low-HDL requirement and recent ACS event). Plus BETonMACE will have a median dosing period 4X that of ASSURE or SUSTAIN. 

BETonMACE could have an equivalent %RRR for 5-point MACE as seen in the Phase 2s, or it could be even better, or it could be worse. Tick tock.

BearDownAZ